Source: Sleep and Breathing Conference 2021
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
Jean-Louis Pépin (Grenoble, France), Jean-Louis Pépin, CHRISTIAN CAUSSE, Ognian Georgev, Rumen Tiholov, ValérieAttali, Johan Verbraecken, Bertien Buyse, Markku Partinen, Ingo Fietze, Georgi Belev, Dejan Dokic, Renaud Tamisier,Patrick Levy, Isabelle Lecomte, Jeanne-Marie Lecomte, Jean-Charles Schwartz, Yves Dauvilliers. Pitolisant long term effect in sleepy obstructive sleep apnea patients with CPAP. Sleep and Breathing Conference 2021

Member's Comments

No comment yet.

Related content which might interest you: Pitolisant long term effect in sleepy obstructive sleep apnea patients without CPAP. Source: Virtual Congress 2021 – Advances in therapeutic plans for sleep disordered breathing Year: 2021 Pitolisant long term effect in sleepy obstructive sleep apnea patients with CPAP. Source: Virtual Congress 2021 – Different treatment modalities and impact of comorbidities on sleep disordered breathing Year: 2021 Effects of long term nCPAP treatment on patients with obstructive sleep apnoea syndrom Source: Eur Respir J 2007; 30: Suppl. 51, 322s Year: 2007 CPAP variability in long term follow-up of OSAS (obstructive sleep apnea syndrome) patients Source: Eur Respir J 2006; 28: Suppl. 50, 412s Year: 2006 CPAP treatment for obstructive sleep apnoea syndrome after CPAP training term Source: Eur Respir J 2002; 20: Suppl. 38, 102s Year: 2002 Auto-titrating CPAP for treating obstructive sleep apnoea, a bimodal response in males? Source: Eur Respir J 2006; 28: Suppl. 50, 409s Year: 2006 Return of sleep apnoea and sleep fragmentation following CPAP withdrawal in patients with obstructive sleep apnoea Source: Eur Respir J, 53 (5) 1802351; 10.1183/13993003.02351-2018 Year: 2019 The effect of CPAP treatment on Galectin-3 level in patients with severe obstructive sleep apnea Source: International Congress 2018 – Cardiovascular and metabolic consequences of sleep-disordered breathing Year: 2018 Daytime hypoxemia in obstructive sleep apnoea (OSA) subjects before CPAP therapy Source: Annual Congress 2009 - Clinical aspects of sleep apnoea Year: 2009 Role of CPAP treatment in elderly with moderate obstructive sleep apnea Source: International Congress 2019 – Treatment of continuous positive airway pressure and monitoring of its effects Year: 2019 Hypercapnia and respiratory drive in obstructive sleep apnoea patients before and after CPAP treatment Source: Eur Respir J 2002; 20: Suppl. 38, 103s Year: 2002 Long-term CPAP compliance in women with obstructive sleep apnoea Source: Annual Congress 2012 - CPAP: beneficial effects on different aspects of health Year: 2012 Does personality change in obstructive sleep apnea (OSA) patients using CPAP? Source: Eur Respir J 2006; 28: Suppl. 50, 409s Year: 2006 Reported but not measured sleep latency predicts successful CPAP therapy in patients with obstructive sleep apnoea Source: Eur Respir J 2002; 20: Suppl. 38, 101s Year: 2002 Should obstructive sleep apnoea be treated regarding the related cardiovascular risk in non sleepy patients? Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 PAI-uPA system in patients with obstructive sleep apnea syndrome (OSAS) in CPAP treatment Source: Annual Congress 2012 - Cardiovascular disease and sleep-disordered breathing Year: 2012 Pitolisant efficacy in excessive daytime sleepiness for patients with obstructive sleep apnea Source: Virtual Congress 2021 – Advances in therapeutic plans for sleep disordered breathing Year: 2021 Pitolisant efficacy in excessive daytime sleepiness for patients with obstructive sleep apnea Source: Sleep and Breathing Conference 2021 Year: 2021 Treatment with CPAP reduces mortality in patients with obstructive sleep apnoea syndrome within less than 3 years Source: Annual Congress 2006 - Therapeutic effects in obstructive sleep apnoea Year: 2006 Cardiovascular regulation effects of CPAP therapy in obstructive sleep apnea patients with and without hypertension during daytime Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II Year: 2012